Abstract There is mounting evidence on the importance of some biological processes in tumor growth, such as vascular supply, apoptosis, autophagy, and senescence. We have investigated these processes in polymorphous low-grade adenocarcinoma (PLGA), in an attempt to identify those that are relevant for this particular lesion. We analyzed 31 cases of PLGA using immunohistochemistry to antibodies against CD34 and CD105 to detect blood vessels; against D2-40 to detect lymphatic vessels; against Bax, Bcl-2, and survivin to explore cell apoptosis; and against Beclin and LCB3 to investigate autophagy and against p21 and p16 to assess senescence. Our results showed that PLGA growth does not depend on newly formed vessels but only on preexisting vasculature. Furthermore, PLGA is promoted by autophagy, sustained by both anti-apoptotic and anti-senescence signals, and stimulated by Bcl-2 and survivin.
Background
Polymorphous low-grade adenocarcinoma (PLGA) is a malignant neoplasm almost exclusively of the minor salivary glands, characterized by cytologic uniformity, morphologic diversity, an infiltrative growth pattern, and low metastatic potential [1] . PLGA was first identified as a specific salivary gland adenocarcinoma almost simultaneously in 1983 by Freedman and Lumerman [2] and Batsakis et al. 1983 [3] . Investigations have since focused mostly on the clinical behavior of the disease which, despite a low risk of metastasis, presents a high risk of morbidity in addition to the potentially disfiguring nature of the treatment [4] .
In order to elucidate how PLGA lesions grow, we assessed some factors deemed essential for tumor growth, such as vascularization, apoptosis, autophagy, and senescence.
Angiogenesis and lymphangiogenesis within the tumor microenvironment are processes that can influence neoplastic growth and metastatic dissemination. Investigating vascularization, imbalances between the mechanisms of cell regulation, proliferation, and death may shed some light on key features of PLGA and contribute to the current knowledge on its growth [5, 6] .
Programmed cell death, which may occur through apoptosis, autophagy, or programmed necrosis, plays an important role in the maintenance of tissue homeostasis, including removal of damaged cells by controlling cell proliferation and death under physiological conditions. In cancer, however, this balance is lost and deregulation of programmed cell death is associated with various stages of carcinogenesis [7] . It has been recognized that apoptosis plays multiple roles in cancer development, growth, and response to treatment [8] . Loss of cell proliferation control and resistance to apoptosis are important mechanisms in tumor growth. Deregulated expression of proteins that control apoptosis can suppress elimination of DNA-damaged cells, which in turn will contribute to accumulation of oncogenic mutations, thus facilitating malignant transformation and tumor development [9] .
Autophagy is a critical cellular mechanism that can prom o t e c e l l s u r v i v a l u n d e r m a n y c i r c u m s t a n c e s . Overactivation of autophagy pathways can, however, lead to cell death [7, 10, 11] . Several studies have demonstrated multidirectional communication between autophagy and carcinogenesis [12, 13] . Autophagy can slow or accelerate the development of tumors, depending on their type, microenvironment and stage [14] .
It has recently been reported that autophagy has a dual role in carcinogenesis: (1) a supervising mechanism protecting normal cells from malignant transformation by recycling damaged organelles, aggregated proteins, mitochondrial abnormalities, damaged DNA, and (2) a mechanism supporting tumor growth by providing nutrients that are critical to tumor cell metabolism [13] .
Senescence is a terminal proliferation arrest mechanism usually related to the aging process. Cumulative evidence, however, has shown that cellular senesence exerts a significant impact on tumourigenesis and degenerative disease [15] [16] [17] . Along with apoptosis, it is considered a failsafe mechanism that prevents cells from transforming into a malignant phenotype.
The aim of this study was to investigate the expression of a panel of biomarkers in PLGA by immunohistochemistry, based on the above-described processes that regulate cell death. Ultimately, the results might provide insight into the possible mechanisms involved in the growth of this particular entity.
Materials and methods

Immunohistochemistry
This study was approved by the Research Ethics Committee of the Sao Leopoldo Mandic Dental School and Research Institute, protocol number 42315715.1.0000.5374
Thirty-one cases of PLGA, previously characterized both morphologically and by immunohistochemistry, composed our sample population. Cases were included based on diagnosis and on a negative history of previous oncological treatment. In our series, no cases of cribriform adenocarcinoma of minor salivary glands (CAMSG) were included, as no cases in our series corresponded to the criteria for a diagnosis of CAMSG.
Immunohistochemical staining was performed using the following antibodies (Table 1) : anti-CD34 and anti-CD105 to detect blood vessels; anti-D2-40 to detect lymphatic vessels; anti-Bax, anti-Bcl-2, and anti-survivin to detect cell apoptosis; anti-Beclin and anti-LCB3 to detect autophagy; and anti-p21 and anti-p16 to detect senescence.
From formalin-fixed paraffin-embedded tumor tissue samples, 5 μm sections were cut and mounted, dewaxed, and rehydrated and endogenous peroxidase activity was quenched by immersing slides in 3% hydrogen peroxide. Antigen retrieval (AR) was achieved by immersing the slides in boiling citrate buffer (pH 6.0) for staining for CD34, Bax, BCl-2, survivin, Beclin, LC3B, p21, and p16. For CD105 staining, AR was performed using 0.4% pepsin, while for D2-40, Tris-EDTA was used (Table 1) . Only the sections for CD105 staining were incubated at 37°C with a serum-free protein blocking solution (code x0909, Dako, SA, Denmark) for 30 min. Subsequently, the sections were incubated with the primary antibody for 60 min (anti-CD34, anti-Bax, anti-Bcl-2, anti-survivin, anti-Beclin, anti-LC3B, anti-P21) or overnight (anti-Cd105, anti-D2-40, anti-P16) at 4°C followed by EnVision polymer HRP and Envision+ (code K1491, DAKO, SA, Denmark) for 1 h at 37°C. The sections were developed for 5 min at 37°C with 3.3′-diaminobenzidine tetrahydrochloride (DAB) and counter-stained with hematoxylin. A negative control was obtained by omitting the primary antibody. No staining was observed on this section.
As incision biopsies only provide a limited amount of tissue for analysis, some paraffin blocks did not contain sufficient material for all immunohistochemistry reactions, hence the different numbers reported in the results.
Density of blood and lymphatic microvessels
For all 31 cases, immunohistochemical staining for CD34, CD105, and D2-40 was interpreted by two experienced pathologists (VCA and ABS) using a double-headed microscope. Vascularization was assessed on all specimen, though only the highest cellular areas were selected for blood vessel quantification. In order to achieve this, images were obtained from 5 fields (hotspots) per case (×40 objective, 0.44 mm field 
Results
The 31 patients included in this study had a mean age of 57.8 years and were mostly female (71%). Data regarding patient demographics and site of the lesions are listed in Table 2 .
Assessed of microvascular density and lymphatic vessel density using anti-D34, CD105, and D2-40 staining
High vascular density was observed in PLGA, with vessels distributed throughout the tumor, both in tumor cell masses and in the stroma. Immunohistochemical staining showed that these vessels were mostly CD34 positive (mean = 12.62), whereas few if any were CD105 positive (mean = 0.34) (Fig. 1a, b) . Only a small number of D2-40-positive (lymphatic) vessels were observed (mean = 0.96) (Fig. 1c) (Fig. 2a) .
Expression of apoptosis markers Bax, Bcl2, and survivin
Bax expression by immunohistochemistry was granular cytoplasmic but remarkably heterogeneous, varying from weak or negative to positive or intense. Six cases (35%) scored 0, three cases (18%) scored 1, six cases (35%) scored 2, and two cases (12%) scored 3 (Fig. 1d) . Strong membrane and cytoplasmic expression of Bcl2 was noted in tumor cells in all cases, with more than 50% of tumor cells positive (score 3) (Fig. 1e) . Survivin expression was observed in both the nucleus and cytoplasm. Twenty-five cases (86%) showed strong diffuse staining for survivin, with more than 50% of tumor cells staining (score 3). Score 2 was observed in two cases (7%) and the remaining two cases (7%) scored 1 ( Fig. 1f) (Fig. 2b) .
The calculated Bax/Bcl2 ratio ranged from 0 to 1, because all Bcl2-positive cases scored 3. The Bax-Bcl2 ratio for most cases (n = 15) was less than 1, suggesting that virtually no apoptosis was taking place. For the remaining two cases, the ratio was 1. 
Expression of autophagy markers Beclin and LC3B
Membrane and cytoplasmic Beclin expression was remarkably heterogeneous, varying between weak or negative and positive or intense. Five cases (22%) scored 0, six cases (26%) scored 1, two cases (9%) scored 2, and 10 cases (43%) scored 3 (Fig. 1g) . Cytoplasmic LC3B expression was strong and diffuse in 17 (85%) Fig. 1 cases (score 3), one case (5%) each scored 0, 1, and 2 ( Fig. 1h) (Fig. 2c) .
Expression of senescence markers p21 and p16
In all cases, nuclear expression of p21 was entirely negative or in less than 10% of tumor cells (score 0) (Fig. 1i) . Most cases were weakly positive for p16, all expression exclusively nuclear. Eighteen (60%) cases scored 0, nine cases (30%) scored 1, two cases (7%) scored 2, and only one case (3%) was strongly positive (score 3) (Fig. 1j) (Fig. 2d) .
Discussion
There is controversy as to whether or not PLGA is a single pathological entity, as recent evidence shows that similar lesions with worse prognosis (notably cribriform adenocarcinoma of the tongue [18] and cribriform adenocarcinoma of the tongue and minor salivary glands (CAMSG) [19] ) may present histologically with features overlapping those of PLGA. CAMSG is considered a unique entity, as it usually arises from the base of the tongue, features cervical lymph node metastases at presentation, and exhibits optically clear nuclei, reminiscent of papillary thyroid cancer [20] . Moreover, in CAMSG, myoepithelial cells are focally present [18, 19] . We included only PLGA and excluded lesions with features of CAMSG or with lymph node metastasis at diagnosis. Our findings shed some light on the possible route through which PLGA lesions grow. As the name suggests, this tumor is of low grade of malignancy, because very few cases with metastatic or recurrent disease have been reported. PLGA may, however, grow to cause considerable local destruction, especially as it affects the palate more than any other intraoral site. Mutilating treatment may contribute to local destruction.
Neo-angiogenesis has been extensively investigated in many tumor types, aiming to identify those that might benefit from antiangiogenic treatment [21] . Our PLGA cases were well vascularized, containing numerous CD34-positive blood vessels surrounding the tumor epithelial cell masses. CD105 immunostaining, however, revealed that most of these vessels were preexisting rather than neo-angiogenic, suggesting that PLGA does not induce neo-angiogenesis. PLGA may instead capitalize on other sources of nutrition to maintain a steady growth.
Metastatic dissemination through the lymphatic system represents one of the major routes through which neoplastic Fig. 2 Distribution of positive cell counts (mean ± SD) or scores (median) associated to each set or immunohistochemical markers. a Box-plot of microvessel density (MVD cell counts) and lymphatic vessel density (LVD cell counts). B Median distribution of cell apoptosis based on Bax, Bcl2, and survivin. C Median distribution of the autophagy-related markers Beclin and LC3B. D Median distribution of the senescence-related markers p21 and p16 disease reaches distant organs, and it is also a key element in determining prognosis [6] . Our results show that lymphatic vessels are scarce and whenever present, confined to the periphery of the lesions. The combination of low neoangiogenesis and poor lymphatic vascularization may explain why metastasis is a rare finding in PLGA.
We found Bcl2 to be strongly and uniformly expressed throughout the PLGA biopsies, whereas Bax expression was weaker and heterogeneous, often within the same lesion. Bax is a pro-apoptotic protein, which is inhibited by Bcl2 in order to bypass cell death. This suggests that rather than the expressed quantity of either protein, the balance between them will determine whether a cell will live or die [22] . As a consequence, the ratio between the level of expression of Bax and Bcl2 might be more informative of the biological behavior of the tumor than that of each marker alone. This is corroborated by the findings from our study, which strongly suggest a shift towards antiapoptosis. In support of this notion, a recent study showed that Bcl2 does not only prevent apoptosis but, in some tumors, also promotes cell migration and invasion [23] .
We also studied cell survival through expression of survivin, which appeared to be strongly expressed in both the nucleus and cytoplasm of PLGA cells. In the cytoplasm, survivin acts as an inhibitor of apoptosis, whereas in the nucleus it is an effector of mitosis and promotes tumor cell proliferation [24] . Only two studies reporting survivin expression in salivary gland tumors have been published, one by Ko et al. [25] focusing on adenoid cystic carcinoma and the other by Ettl et al. [26] on survivin expression in 286 salivary gland carcinomas, including 11 cases of PLGA. Both concluded that nuclear expression of survivin is associated with high-grade malignancy. Since the latter study identified survivin expression in the nucleus, it is conceivable that the location of expression of a protein depends upon the tumor type on which the study was performed. This implies that data on immunohistochemical expression should be cautiously interpreted, and should include other biological mechanisms that stimulate tumor growth. For PLGA, our findings strongly suggest that apoptosis is properly regulated while cell proliferation might be stimulated by Bcl2 and nuclear expression of survivin.
We also investigated cell death via autophagy, using Beclin and LC3B as biomarkers. Autophagy is an important mechanism of cell survival under nutrient and energy starvation and hypoxia [7, 27] . Our results show that both autophagy markers are strongly expressed in PLGA cells, suggesting that in PLGA autophagy is an important mechanism to support tumor growth. Therefore, therapeutic strategies designed to control or inhibit autophagy ought to be considered, as has been proposed for other tumors [13] .
Several studies have focused on cross-talk between apoptosis and autophagy, as comprehensively discussed in the review by El-Khattouti et al. [28] . Suppression of apoptosis induces autophagy and inhibition of autophagy leads to apoptosis, key aspects of tumor behavior to be taken into account when planning treatment.
Senescence has been suggested as the resultant of tumor suppressor pathways. Physiologically, in aging cells, shortening telomeres activate the p53-p21-pRB pathway, whereas in neoplasia this pathway is activated through p16-pRB. Conceivably, p21 may transiently inhibit pRB, with p16 inducing a state of permanent pRB hypophosphorylation [29, 30] . This provided the rationale for our investigation on expression of p21 and p16 in PLGA, even though they are not regarded as specific markers of senescence. Our results show that PLGA cells do not express p21 and only a small proportion of lesions express p16, though weak at best (<50%). These findings suggest that abrogation of senescence pathways may be an additional route to PLGA growth.
We investigated vascularization of PLGA and found it to be well vascularized but not dependent on newly formed vessels. PLGA appear to grow at the expense of autophagy, sustained by anti-apoptotic and anti-senescence signals and stimulated by Bcl2 and survivin, the former providing a link to cell migration and invasion and the latter to proliferation.
In summary, the findings from this study provide new insight into the natural history of PLGA, which ought to be taken into consideration when designing novel therapeutic strategies. These should reduce mutilating approaches, which will improve the quality of life of patients diagnosed with this disease.
